PhoreMost has published new data validating its GlueSEEKER platform, a high-throughput technology designed to accelerate ...

Scientists have uncovered a molecular "on–off" switch that helps lung adenocarcinoma—the most common form of lung cancer—grow ...

PhoreMost Ltd., a next-generation targeted protein degradation (TPD) company progressing a pipeline of degrader therapeutics within oncology and inflammation, today announced the publication of a ...

Genomics, Inc. (Nasdaq: TXG), a leader in single cell and spatial biology, and the A*STAR Genome Institute of Singapore ...

Around 10 million people globally live with the life-threatening virus HTLV-1. Yet it remains a poorly understood disease ...

Colon cancer is often driven by cancer stem cells, which resist treatment and lead to relapse. In a recent study, researchers ...

Elix is a Japan-based AI drug discovery company with a mission to "Rethinking drug discovery," providing services to ...

Drug discovery has long been criticized for its slow, costly, and failure-prone nature. Traditional approaches, particularly ...

In an industry where 90 percent of drug candidates fail before reaching the market, a handful of startups are betting ...